BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
BioNexus Gene Lab's operating cash flow for the twelve months ending Jun 30, 2026 was -$846.57K. For fiscal 2025 it was -$1.84M. The highest annual figure on record is $552.68K in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.84M | – |
| FY2024 | Dec 31, 2024 | -$2.09M | – |
| FY2023 | Dec 31, 2023 | -$1.82M | -430.2% |
| FY2022 | Dec 31, 2022 | $551.82K | +5923.6% |
| FY2021 | Dec 31, 2021 | $9.16K | -98.3% |
| FY2020 | Dec 31, 2020 | $552.68K | – |
| FY2019 | Dec 31, 2019 | -$217.27K | – |
| FY2018 | Dec 31, 2018 | -$274.08K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$422.49K | – |
| Q1 FY2026 | Mar 31, 2026 | -$147.67K | – |
| Q4 FY2025 | Dec 31, 2025 | $961.06K | +338.4% |
| Q3 FY2025 | Sep 30, 2025 | -$1.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -$737.91K | – |
| Q1 FY2025 | Mar 31, 2025 | -$824.07K | – |
| Q4 FY2024 | Dec 31, 2024 | $219.20K | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$672.28K | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.15K | – |
| Q4 FY2023 | Dec 31, 2023 | -$782.53K | -264.1% |
| Q3 FY2023 | Sep 30, 2023 | -$899.35K | -391.2% |
| Q2 FY2023 | Jun 30, 2023 | -$23.82K | – |
| Q1 FY2023 | Mar 31, 2023 | -$116.52K | – |
| Q4 FY2022 | Dec 31, 2022 | $476.74K | -1.3% |
| Q3 FY2022 | Sep 30, 2022 | $308.89K | -2.2% |
| Q2 FY2022 | Jun 30, 2022 | -$195.97K | – |
| Q1 FY2022 | Mar 31, 2022 | -$37.84K | -132.8% |
| Q4 FY2021 | Dec 31, 2021 | $483.01K | -48.2% |
| Q3 FY2021 | Sep 30, 2021 | $315.87K | -58.1% |
| Q2 FY2021 | Jun 30, 2021 | -$905.14K | – |
| Q1 FY2021 | Mar 31, 2021 | $115.43K | – |
| Q4 FY2020 | Dec 31, 2020 | $932.48K | – |
| Q3 FY2020 | Sep 30, 2020 | $754.74K | – |
| Q2 FY2020 | Jun 30, 2020 | -$157.20K | – |
| Q1 FY2020 | Mar 31, 2020 | -$977.35K | – |
| Q4 FY2019 | Dec 31, 2019 | -$58.36K | -123.9% |
| Q3 FY2019 | Sep 30, 2019 | -$57.42K | -132.5% |
| Q2 FY2019 | Jun 30, 2019 | -$52.94K | – |
| Q1 FY2019 | Mar 31, 2019 | -$48.56K | – |
| Q4 FY2018 | Dec 31, 2018 | $243.79K | – |
| Q3 FY2018 | Sep 30, 2018 | $176.53K | – |
| Q2 FY2018 | Jun 30, 2018 | -$20.83K | – |
| Q1 FY2018 | Mar 31, 2018 | -$673.56K | – |
See a number that looks wrong?